BBOT — BridgeBio Oncology Therapeutics Inc. stock price, charts and financials
QT35BridgeBio Oncology Therapeutics Inc.BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 32.06% | Shs Outstand | 80.11M | Perf Week | -3.64% |
| Market Cap | 382.11M | Forward P/E | - | EPS next Y | -2.49 | Insider Trans | 0.00% | Shs Float | 452.99K | Perf Month | -50.31% |
| Enterprise Value | 330.56M | PEG | 0.00 | EPS next Q | -0.66 | Inst Own | - | Short Float | 7.73% | Perf Quarter | -36.90% |
| Income | -182.23B | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 16.52 | Perf Half Y | -47.29% |
| Sales | 0.00 | P/B | 0.00 | EPS next Y | 4.22% | ROA | -48.34% | Short Interest | 6.19M | Perf YTD | -61.90% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -46.90% | 52W High | 14.87 -67.92% | Perf Year | -55.79% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -61.10% | 52W Low | 4.69 1.71% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.42% 7.25% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 99.95% | Oper. Margin | 0.00% | ATR (14) | 0.55 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.69 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 19.20 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.69 | EPS Q/Q | 98.60% | SMA20 | -36.23% | Beta | 1.58 | Target Price | 19.00 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | - | SMA50 | -42.30% | Rel Volume | 2.73 | Prev Close | 4.89 |
| Employees | 88 | LT Debt/Eq | 0.00 | Earnings | Nov 11 | SMA200 | -49.63% | Avg Volume | 451.07K | Price | 4.77 |
| IPO Date | Aug 12, 2025 | Option/Short | No / Yes | EPS/Sales Surpr. | -24.81% - | Net Debt/EBITDA | 0.26 | Volume | 1,229,848 | Change | -2.45% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | Stifel Nicolaus | $15 | |
| Sep-09-26 | Reiterated | Raymond James | Outperform | |
| Sep-09-26 | Reiterated | Canaccord Genuity | Buy | |
| May-11-26 | Initiated | Canaccord | Buy | |
| Feb-10-26 | Initiated | Stifel | Buy | |
| Jan-09-26 | Initiated | Raymond James | Outperform | |
| Jan-08-26 | Reiterated | Morgan Stanley | $18 | |
| Dec-05-25 | Initiated | Morgan Stanley | Overweight | |
| Sep-17-25 | Initiated | Leerink | Outperform | |
| Sep-15-25 | Initiated | H.C | Buy |
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | |
| Selling, General and Administrative Excl. Other | 25 | 8 | 8 | — | — | |
| Research and Development | 121 | 73 | 56 | — | — | |
| Other Operating Expense | 0 | 0 | 1 | — | — | |
| Operating Income | -146 | -81 | -65 | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | |
| Unusual Expense | — | — | — | — | — | |
| Non-Operating Income (Expense) | 12 | 7 | 0 | — | — | |
| Net Income Before Taxes | -134 | -74 | -65 | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | |
| Consolidated Net Income | -134 | -74 | -65 | — | — | |
| Net Income From Continuing Operations | -134 | -74 | -65 | — | — | |
| Net Income | -134 | -74 | -65 | — | — | |
| EPS (Recurring) | -4.30 | -5,756.41 | -0.00 | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.30 | -5,756.41 | -0.00 | — | — | |
| EPS (Diluted) | -4.30 | -5,756.41 | -3.16 | — | — | |
| EBITDA | -145 | -81 | -65 | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | |
| Shares Outstanding | 31 | 0 | 20 | — | — | |
| Market Capitalization | 388 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Chen Bihua | director, 10 percent owner: | Aug 11 '25 | Option Exercise | 0.00 | 4,172,126 | 417 | 4,681,126 | Aug 13 |
| Holman Albert A III | other: Former Director | Aug 11 '25 | Option Exercise | 0.00 | 30,000 | 0 | 30,000 | Aug 11 |
| McKenna Mark C. | other: Former Director | Aug 11 '25 | Option Exercise | 0.00 | 30,000 | 0 | 30,000 | Aug 11 |
| Schmid John P. | other: Former Director | Aug 11 '25 | Option Exercise | 0.00 | 30,000 | 0 | 30,000 | Aug 11 |